1.28
price down icon7.97%   -0.10
 
loading
Schlusskurs vom Vortag:
$1.38
Offen:
$1.35
24-Stunden-Volumen:
344.35K
Relative Volume:
0.53
Marktkapitalisierung:
$85.26M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-46.12M
KGV:
-1.4811
EPS:
-0.8642
Netto-Cashflow:
$-41.02M
1W Leistung:
-15.89%
1M Leistung:
-19.62%
6M Leistung:
-26.59%
1J Leistung:
-18.59%
1-Tages-Spanne:
Value
$1.26
$1.355
1-Wochen-Bereich:
Value
$1.26
$1.55
52-Wochen-Spanne:
Value
$0.7113
$2.815

Inflarx N V Stock (IFRX) Company Profile

Name
Firmenname
Inflarx N V
Name
Telefon
-
Name
Adresse
-
Name
Mitarbeiter
74
Name
Twitter
Name
Nächster Verdiensttermin
2025-03-21
Name
Neueste SEC-Einreichungen
Name
IFRX's Discussions on Twitter

Vergleichen Sie IFRX mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
IFRX
Inflarx N V
1.27 93.49M 0 -46.12M -41.02M -0.8642
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
425.12 109.22B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
631.77 67.50B 14.25B 4.58B 3.88B 41.77
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
426.00 57.35B 3.21B 43.57M 221.36M 0.2405
Biotechnology icon
ARGX
Argen X Se Adr
838.04 50.87B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
INSM
Insmed Inc
184.21 39.72B 447.02M -1.18B -868.57M -6.1812

Inflarx N V Stock (IFRX) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-09-02 Fortgesetzt H.C. Wainwright Buy
2025-05-29 Herabstufung Raymond James Strong Buy → Outperform
2025-04-29 Eingeleitet Cantor Fitzgerald Overweight
2023-04-05 Hochstufung Guggenheim Neutral → Buy
2022-02-28 Herabstufung Guggenheim Buy → Neutral
2021-10-28 Hochstufung Raymond James Outperform → Strong Buy
2021-03-11 Hochstufung Guggenheim Neutral → Buy
2020-11-06 Hochstufung SVB Leerink Mkt Perform → Outperform
2020-10-08 Eingeleitet H.C. Wainwright Buy
2020-06-17 Eingeleitet BTIG Research Buy
2020-04-30 Hochstufung Raymond James Mkt Perform → Outperform
2019-06-05 Herabstufung BMO Capital Markets Outperform → Market Perform
2019-06-05 Herabstufung Guggenheim Buy → Neutral
2019-06-05 Herabstufung JP Morgan Overweight → Underweight
2019-06-05 Herabstufung Robert W. Baird Outperform → Neutral
2019-06-05 Herabstufung SunTrust Buy → Hold
2019-01-29 Eingeleitet Robert W. Baird Outperform
2018-12-10 Eingeleitet Credit Suisse Outperform
2018-07-13 Eingeleitet BMO Capital Markets Outperform
2018-06-28 Eingeleitet Raymond James Outperform
2018-06-28 Eingeleitet SunTrust Buy
2018-02-08 Eingeleitet B. Riley FBR, Inc. Buy
Alle ansehen

Inflarx N V Aktie (IFRX) Neueste Nachrichten

pulisher
10:16 AM

InflaRx NV expected to post a loss of 15 cents a shareEarnings Preview - TradingView

10:16 AM
pulisher
08:48 AM

Perhaps timely catching InflaRx N.V (IFRX) would be a good idea - setenews.com

08:48 AM
pulisher
06:48 AM

Why InflaRx N.V. stock remains a top recommendationJuly 2025 Review & Long Hold Capital Preservation Plans - newser.com

06:48 AM
pulisher
03:48 AM

InflaRx N.V. stock prediction for this weekJuly 2025 Decliners & Low Drawdown Investment Strategies - newser.com

03:48 AM
pulisher
Nov 03, 2025

Will InflaRx N.V. stock see PE expansionWeekly Trade Analysis & Consistent Profit Trade Alerts - newser.com

Nov 03, 2025
pulisher
Nov 03, 2025

Will InflaRx N.V. (IF0) stock outperform benchmarksWeekly Trend Summary & Safe Entry Point Alerts - newser.com

Nov 03, 2025
pulisher
Nov 03, 2025

Why InflaRx N.V. (IF0) stock benefits from AI revolutionJuly 2025 Trends & Weekly Setup with ROI Potential - newser.com

Nov 03, 2025
pulisher
Nov 03, 2025

Why InflaRx N.V. stock is considered a top pickJuly 2025 Patterns & Verified Chart Pattern Trade Signals - newser.com

Nov 03, 2025
pulisher
Nov 03, 2025

What hedge fund moves indicate for InflaRx N.V. (IF0) stockTrade Entry Report & Fast Exit and Entry Strategy Plans - newser.com

Nov 03, 2025
pulisher
Nov 03, 2025

Can InflaRx N.V. recover in the next quarter2025 Trading Recap & Risk Controlled Swing Alerts - newser.com

Nov 03, 2025
pulisher
Nov 03, 2025

Will InflaRx N.V. (IF0) stock deliver compounding returnsJuly 2025 PreEarnings & Real-Time Price Movement Reports - newser.com

Nov 03, 2025
pulisher
Nov 02, 2025

What makes InflaRx N.V. stock attractive to growth fundsTrade Exit Report & Verified Swing Trading Watchlists - newser.com

Nov 02, 2025
pulisher
Nov 02, 2025

How geopolitical tensions affect InflaRx N.V. stockBear Alert & Risk Managed Investment Strategies - newser.com

Nov 02, 2025
pulisher
Nov 02, 2025

Institutional scanner results for InflaRx N.V.Weekly Market Report & Daily Technical Stock Forecast Reports - newser.com

Nov 02, 2025
pulisher
Nov 02, 2025

Total debt per share of InflaRx N.V. – MUN:IF0 - TradingView

Nov 02, 2025
pulisher
Nov 02, 2025

Reversal indicators forming on InflaRx N.V. stock2025 Sector Review & Daily Chart Pattern Signal Reports - newser.com

Nov 02, 2025
pulisher
Nov 01, 2025

How InflaRx N.V. stock performs after earningsGap Up & Safe Capital Allocation Plans - newser.com

Nov 01, 2025
pulisher
Nov 01, 2025

Volatility clustering patterns for InflaRx N.V.Recession Risk & Technical Pattern Recognition Alerts - newser.com

Nov 01, 2025
pulisher
Nov 01, 2025

InflaRx NV IF0 Stock Analysis and ForecastEarnings Growth Projections & Learn to Think Like a Long-Term Investor - earlytimes.in

Nov 01, 2025
pulisher
Nov 01, 2025

InflaRx N.V. (NASDAQ:IFRX) Short Interest Update - MarketBeat

Nov 01, 2025
pulisher
Nov 01, 2025

How reliable is InflaRx N.V. (IF0) stock dividend growthIPO Watch & Daily Profit Maximizing Tips - newser.com

Nov 01, 2025
pulisher
Oct 31, 2025

Can InflaRx N.V. stock rebound after recent weaknessTrade Volume Summary & Daily Chart Pattern Signals - newser.com

Oct 31, 2025
pulisher
Oct 31, 2025

Will InflaRx N.V. (IF0) stock deliver stable dividends2025 Winners & Losers & High Win Rate Trade Tips - newser.com

Oct 31, 2025
pulisher
Oct 30, 2025

Edesa Biotech and InflaRx: Advancing ARDS Treatment with Vilobelimab - MSN

Oct 30, 2025
pulisher
Oct 30, 2025

InflaRx’s Phase 2a Study on INF904: A Potential Game-Changer for Chronic Conditions - MSN

Oct 30, 2025
pulisher
Oct 30, 2025

Edesa Biotech and InflaRx: Breathing New Life into ARDS Treatment - MSN

Oct 30, 2025
pulisher
Oct 29, 2025

InflaRx N.V. (NASDAQ:IFRX) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat

Oct 29, 2025

Finanzdaten der Inflarx N V-Aktie (IFRX)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$37.73
price up icon 1.14%
$28.95
price up icon 0.80%
$101.78
price up icon 0.23%
$103.95
price down icon 0.01%
biotechnology ONC
$311.95
price down icon 0.20%
$184.44
price down icon 1.00%
Kapitalisierung:     |  Volumen (24h):